Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Kirn

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
Surgical Oncology Clinics of North America|December 19, 2002
Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyondRobert S Warren, David H Kirn
Current Cancer Drug Targets|March 10, 2007
From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus developmentAnne Moon Crompton, David H Kirn
Das Medizinische Laboratorium|January 1, 1972
[Computer program for rapid analysis of acid-base parameters]V M Roemer, H Kirn, H Rüttgers
Bulletin of Mathematical Biology|June 24, 2004
Analysis of a three-way race between tumor growth, a replication-competent virus and an immune responseJoseph T Wu, David H Kirn, Lawrence M Wein
Current Gene Therapy|August 17, 2005
The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?Stephen H Thorne, David L Bartlett, David H Kirn
Methods in Molecular Biology (Clifton, N.J.)|August 6, 2008
Oncolytic adenoviruses for cancer gene therapyTa-Chiang Liu, Stephen H Thorne, David H Kirn
Current Opinion in Molecular Therapeutics|August 27, 2005
Vaccinia virus and oncolytic virotherapy of cancerStephen H Thorne, Tae Ho Hwang, David H Kirn
Cancer Research|March 22, 2003
Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and deliveryLawrence M Wein, Joseph T Wu, David H Kirn
Cancer Gene Therapy|December 23, 1999
Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effectsC C Heise, A Williams, J Olesch, et al.
Molecular Therapy. Oncology|March 11, 2026
Intravenous oncolytic vaccinia expressing transgenes for enhanced safety, inhibition of shedding, imaging, and systemic cancer immunotherapyLiliana Maruri-Avidal, Prajit Limsirichai, Nathaniel Gulizia, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Surgical Oncology Clinics of North America|December 19, 2002
Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyondRobert S Warren, David H Kirn
Current Cancer Drug Targets|March 10, 2007
From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus developmentAnne Moon Crompton, David H Kirn
Das Medizinische Laboratorium|January 1, 1972
[Computer program for rapid analysis of acid-base parameters]V M Roemer, H Kirn, H Rüttgers
Bulletin of Mathematical Biology|June 24, 2004
Analysis of a three-way race between tumor growth, a replication-competent virus and an immune responseJoseph T Wu, David H Kirn, Lawrence M Wein
Current Gene Therapy|August 17, 2005
The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?Stephen H Thorne, David L Bartlett, David H Kirn
Methods in Molecular Biology (Clifton, N.J.)|August 6, 2008
Oncolytic adenoviruses for cancer gene therapyTa-Chiang Liu, Stephen H Thorne, David H Kirn
Current Opinion in Molecular Therapeutics|August 27, 2005
Vaccinia virus and oncolytic virotherapy of cancerStephen H Thorne, Tae Ho Hwang, David H Kirn
Cancer Research|March 22, 2003
Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and deliveryLawrence M Wein, Joseph T Wu, David H Kirn
Cancer Gene Therapy|December 23, 1999
Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effectsC C Heise, A Williams, J Olesch, et al.
Molecular Therapy. Oncology|March 11, 2026
Intravenous oncolytic vaccinia expressing transgenes for enhanced safety, inhibition of shedding, imaging, and systemic cancer immunotherapyLiliana Maruri-Avidal, Prajit Limsirichai, Nathaniel Gulizia, et al.
Pageof 8